Indoco Remedies Limited — Q2 FY26 earnings call

Call held 6 Nov 2025

Management summary

Indoco Remedies reported a strong Q2 FY26 with consolidated revenue growth of 9.5% YoY and significant QoQ EBITDA margin expansion, signaling a turnaround from previous challenges. Regulatory progress was positive with a clean US FDA inspection of its API facility and tentative approval for Canagliflozin. While the company faces ongoing remediation costs and losses in subsidiaries, management is confident in future growth, debt reduction, and margin improvement through strategic focus on vertically integrated products and cost control.

Highlights

  • Consolidated net revenues for Q2 FY26 increased by 9.5% YoY to ₹471.8 crores, and 9.5% QoQ.

  • Standalone EBITDA margin significantly improved to 12.4% (₹53.4 crores) in Q2 FY26 from 3.8% (₹14.8 crores) in Q1 FY26.

  • US FDA successfully completed an inspection of the API manufacturing facility at Patalganga with 0 observations.

  • Management expects double-digit growth in Europe/UK business from Q3 FY26 onwards, targeting ₹300 crores revenue by FY27.

  • Received tentative US FDA approval for Canagliflozin in November 2025, a product filed 4 years ago.

Concerns

  • US FDA remediation costs at Plant 2 are expected to continue for another 2 quarters, impacting other expenses.

  • The ₹5,000 crore revenue target for 2027 is now expected to be delayed by approximately 18 months beyond 2027.

  • Subsidiaries FPP and Warren Remedies reported a combined loss of ₹23 crores this quarter, with Warren Remedies expected to continue bleeding for another 2 quarters.

  • Interest payments have increased significantly, with a current run rate of ₹100 crores quarterly compared to ₹10-11 crores annually previously.

Key financials

  1. Consolidated Net Revenues ₹471.8 Cr +9.5%YoY
  2. Standalone Net Revenues ₹429.3 Cr +8.8%YoY
  3. Consolidated EBITDA ₹43.1 Cr +6.9%YoY
  4. Consolidated EBITDA Margin 9.1% -0.2%YoY
  5. Standalone EBITDA ₹53.4 Cr +0.9%YoY
  6. Standalone EBITDA Margin 12.4% -1%YoY

What they filed

Q1 FY27: revenue up 6.4%, net profit up 280.6% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue433 411 390 440 485 +12%445 +8%476 +22%468 +6%
EBITDA40 12 -1 18 43 +8%32 +167%50 +5100%41 +128%
Net profit-10 -28 -41 -36 -9 +10%-29 −4%-24 +41%65 +281%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

Share of Revenue
Domestic Formulation ₹226.1 Cr 33.7%
International Formulation ₹153.3 Cr 22.8%
Regulated Markets ₹91.5 Cr 13.6%
Emerging Markets ₹61.8 Cr 9.2%
Europe Business ₹54.7 Cr 8.2%
API Business ₹43.1 Cr 6.4%
US Business ₹33.6 Cr 5.0%
AnaCipher CRO & Indoco Analytical Solutions ₹6.8 Cr 1.0%

Capital allocation

high confidence
  • Capex Capex disclosed
    no any further specific capex, which is required for at least next few years because we have now a good amount of capacity which is available to utilize. We have done a lot of projects on increasing the efficiency in particularly in Baddi I, Baddi II and Goa I, our plant. So that should give us a decent margins. That will increase our overall capex -- overall cash flow.
  • Debt Debt disclosed
    • Repayment Commitment to repay in the next half of FY26. ₹52 Cr
    • Repayment Commitment to repay in the year after H2 FY26. ₹140 Cr
    This year itself, we repaid certain loan in first half. And our commitment to repay in the next half, that is the second half of this particular year is close to about INR52 crores. And a year after that, close to about INR140 crores.

Guidance & targets

Revenue

  • Europe/UK Business Growth Revenue · from Q3 FY26 onwards · High confidence double-digit growth
    I expect that at least from here on, we should be able to show a double-digit growth in Europe, U.K. business.

    — Aditi Panandikar

  • Total Revenue Revenue · 18 months beyond 2027 (mid-2029) · Medium confidence ₹5,000 crores

    Previously ₹5,000 crores by 2027 → ₹5,000 crores

    INR5,000 crore in 2027, which was our immediate agenda, looks a little bit distant at this stage. I feel that we will have to take a delay of probably 18 months to realize that beyond 2027.

    — Aditi Panandikar

  • Total Revenue Revenue · in 3 years (FY29) · High confidence ₹3,500 crores
    From here in 3 years, I feel confident to be in the region of around INR3,500 crores.

    — Aditi Panandikar

  • Europe Revenue Revenue · next year (FY27) · High confidence ₹300 crores
    next year itself, we should be able to do it [INR300 crores].

    — Aditi Panandikar

  • Incremental US Revenue (from 2 lines) Revenue · in a clean quarter after US FDA audit · Medium confidence ₹30 crores
    In a clean quarter after U.S. FDA audit with everything going fine, we can definitely expect INR30 crores incremental.

    — Aditi Panandikar

R&D Spend

  • R&D Spend as % of Sales R&D Spend · in the very first year (FY27) · High confidence 4%

    Previously 5% → 4%

    R&D hovering at 5% of our sales. But as the sales pick up, I think we should -- going forward, we can bring it easily down to 4% in the very first year.

    — Aditi Panandikar

Profitability

  • FPP Breakeven Profitability · in a couple of quarters · High confidence breakeven
    in a couple of quarters, FPP should be able to break even.

    — Aditi Panandikar

  • Warren Remedies (WRPL) Breakeven Profitability · next year (FY27) · Medium confidence EBITDA breakeven
    At EBITDA levels, we should, not sure about that [PAT breakeven by FY27]. Let's clear these 2 quarters, which are going to be challenging. And maybe next year itself, we can surprise you a bit.

    — Aditi Panandikar

What to watch in Q3 FY26

US FDA audit for Plant 2 and approval of remaining lines

next quarter / Q4 FY26
Current Acknowledgment received, audit pending
Target US FDA audit completed, progress on approvals

Why it matters

Resolution of US FDA issues is key to unlocking full manufacturing capacity and revenue potential from sterile products.

And just this morning, we have got a receipt from U.S. FDA saying that they acknowledge that we are ready. So which is the first positive communication we have got from their side that they acknowledge that we are ready. So we will now look forward to them coming down soon.

Risks & concerns

  • US FDA remediation costs at Plant 2

    medium

    Remediation costs related to USFDA at Plant 2 are expected to continue for another 2 quarters.

    Management acknowledged

  • Slow US FDA approval process for sterile lines

    medium

    Only 2 of 4 sterile lines in Goa are functional, and the largest line (Line 1) is still not approved, causing delays in product supply.

    Management acknowledged

  • Losses in subsidiaries (FPP and Warren Remedies)

    medium

    FPP and Warren Remedies reported a combined loss of ₹23 crores this quarter, with Warren Remedies expected to continue bleeding for another 2 quarters.

    Analyst acknowledged

  • Rising debt and high interest costs

    medium

    Interest payments have increased significantly to a quarterly run rate of ₹100 crores, raising concerns about sustainability.

    Analyst acknowledged

  • Impact of seasonal portfolio on India business

    low

    Unusual weather patterns (prolonged rains) impacted sales of seasonal products like Cyclopam and Cital.

    Management acknowledged

  • Initial years of OTC business draining margins

    low

    The initial years of the OTC business require significant advertising budgets, which will be 'draining on the margin'.

    Management acknowledged

Q&A highlights

5 direct
US FDA approval for remaining sterile lines at Goa Partial
So only the product mix, which was running on these 2 lines, one of which is injectable, and the other is ophthalmic, we are allowed to make. And much of the time, as I told you, has gone into media fill, getting the partner sort of up and about and allowing us to supply. Our largest line was Line 1, which is still not approved.

Highlights the ongoing delays and partial approval for US sterile manufacturing, impacting revenue potential.

Asked by Madhav

Control of other expenses and remediation costs Direct
the recurring kind of other expenses, in fact, are being very well brought under control, such as lab expenses, your spares and all the other plant-related efficiency related, those are coming under control. In other expenses for us, we continue to have the remediation costs, which are related to the USFDA remediation at Plant 2. And these specifically are likely to go on for another 2 quarters.

Clarifies that while general expenses are controlled, specific remediation costs for Plant 2 will persist for two more quarters, impacting profitability.

Asked by Nirmam

Sale of fixed assets and cash flow Direct
On the cash flow front, this INR45 crores is equipment from the Waluj plant, which we have resorted to a sale and leaseback transaction, and that's what you're seeing there. ... In 2 lots, it was done totalling to very close to INR50 crores.

Explains a significant cash inflow in H1 FY26 was from a one-time sale and leaseback transaction, not core operations.

Asked by Nirmam

Negative net worth and impairment for FPP and Warren Remedies subsidiaries Direct
For FPP, the company we acquired in 2023, used to be in the business of trading. So they had licensed in so we have licensed in a couple of products from some people to continue that business. So this is a business where a third party makes the product and FPP is a trading partner to sell in U.S. okay? ... The second subsidiary, which you talked about WRPL, the Warren remedies. In Warren remedies, there are 2 part of business. One is the OTC business, which launched last year. And second one is API intermediates and API finished goods.

Management explains the strategic rationale and operational status of the loss-making subsidiaries, indicating confidence in their turnaround.

Asked by Sajal Kapoor

Rising debt profile and sustainability Direct
This year itself, we repaid certain loan in first half. And our commitment to repay in the next half, that is the second half of this particular year is close to about INR52 crores. And a year after that, close to about INR140 crores. So we are definitely confident in terms of generating that much cash flow, including supporting for the finance.

Addresses analyst's concern about rising debt and interest costs by outlining specific debt repayment plans for the current and next fiscal year.

Asked by Sajal Kapoor

Warren Remedies (WRPL) breakeven timeline Partial
At EBITDA levels, we should, not sure about that [PAT breakeven by FY27]. Let's clear these 2 quarters, which are going to be challenging. And maybe next year itself, we can surprise you a bit.

Management provides a more cautious outlook on WRPL's breakeven, suggesting EBITDA breakeven might be achievable by FY27, but PAT breakeven is less certain.

Asked by Naysar

Europe revenue reduction from Q1 to Q2 Direct
So we had some challenges with one of our products on distribution side and a, but more importantly, if you look at U.S. in the same period, it has increased. So like I said earlier, some of our customers, they had not entirely shifted to the new sites for Europe, but our commitments to U.S. customers from the erstwhile sites were already there. So some of the volume from Plant 1 in Goa has been committed to U.S. to supply, say, Glimipiride, which is increasing leaps and bounds. And we have had Europe to queue in at Baddi III so that some supplies got delayed. But it will get evened out going forward.

Explains the QoQ decline in Europe revenue due to distribution challenges and diversion of some production to meet US commitments, with an expectation of normalization.

Asked by Madhav

2 min read 6 chapters

Detailed narrative

Q2 FY26 Performance Overview and Turnaround

Indoco Remedies reported a strong Q2 FY26, marking the first quarter of an uptick in performance after a challenging previous year. Consolidated net revenues grew 9.5% YoY to ₹471.8 crores, with standalone net revenues increasing 8.8% YoY to ₹429.3 crores. The company achieved a significant QoQ improvement in standalone EBITDA margin, rising to 12.4% (₹53.4 crores) from 3.8% (₹14.8 crores) in Q1 FY26, demonstrating progress in cost control and efficiency.

Regulatory and Product Pipeline Updates

The US FDA completed an inspection of the API manufacturing facility at Patalganga with zero observations, a positive regulatory outcome. Furthermore, the company received tentative US FDA approval for Canagliflozin in November 2025, a product filed four years prior, with sales expected to commence in 2028. In the India market, Indoco launched six new products across anti-infective, respiratory, and dental segments, including Vepazil 250/500 and Tuspel AA.

International Business Performance and Outlook

International formulation revenues grew 21.5% YoY to ₹153.3 crores. US business revenue saw a 36% YoY increase to ₹33.6 crores. While Europe revenue declined 8.7% YoY to ₹54.7 crores due to distribution challenges and diversion of production to the US, management expects a double-digit growth from Q3 FY26 onwards, targeting ₹300 crores in annual revenue by FY27. The company is also focusing on derisking its US strategy by leveraging CMOs rather than upfront investments.

Subsidiary Performance and Strategy

Subsidiaries FPP and Warren Remedies (WRPL) reported a combined loss of ₹23 crores this quarter. FPP is expected to break even in a couple of quarters, while WRPL, which includes OTC and API intermediates, is projected to continue bleeding for another two quarters, with EBITDA breakeven anticipated by FY27. The OTC business, though initially margin-draining due to advertising, is seen as a strategic investment for brand building and market expansion.

Capital Allocation and Debt Management

The company has completed heavy capex investments over the last two years and anticipates no further significant capex for the next few years, focusing instead on maintenance capex of ₹50-70 crores annually. Management acknowledged the rising debt profile and increased interest costs, committing to repay ₹52 crores in H2 FY26 and ₹140 crores in FY27. Operating cash flow in Q2 FY26 was almost equal to the entire last year's generation, supporting debt reduction efforts.

Revised Revenue Targets and R&D Focus

The ambitious ₹5,000 crore revenue target for 2027 has been revised, now expected to be realized approximately 18 months beyond 2027. A new target of around ₹3,500 crores in revenue is set for three years from now (FY29). R&D spend, currently hovering at 5% of sales, is targeted to be reduced to 4% in FY27, with a strategic focus on vertically integrated API products and volume builders rather than high-risk Para IV opportunities.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls